Please assess the completion status of the following clinical trial:

Trial Title: PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Brain injured patients with a Glasgow scale score ≤ 12 who require ventilation more than 48 hours~Exclusion Criteria:~* Patient with a high risk of death within the 48 first hours after admission,~* Patient intubated for more than12 hours~* Intubation after the 48th hours after admission~* Coverage to cardiopulmonary arrest~* Coma due to a tumor, an infectious disease or a cardiac arrest~* Previous hospitalisation within the last month before admission for coma~* béta-lactamines allergy~* Patient who receive already antibiotics at the admission for a previous infection~* Prophylactic antibiotic due to be done within 24 hours following the randomisation~* Patient Intubated through a tracheal tube with subglottic secretion aspiration~* Patient with a tracheotomy~* Patient or family refuse to be involved in the study~* Use of Ceftriaxone within 2 days before enrolment~* Participation in another research protocol focusing on an anti-infective treatment or on a measure decreasing the risk of infection~* Patients not affiliated to a social security scheme, Pregnant woman or breast-feeding mother, Patients deprived of their liberty by judicial or administrative decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftriaxone (Type: EXPERIMENTAL): None
- Sodium Chloride (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).